Brought to you by 
Biogen and Celltech develop Crohn's disease drug; development halted
17 Jan 2012
Executive Summary
Biogen and Celltech will research, develop, manufacture, and market CDP571, Celltech's humanized anti-TNF-alpha antibody, which is in Phase III trials for Crohn's disease. The companies will also test the compound for other inflammatory indications, such as psoriasis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen and Celltech develop Crohn's disease drug; development halted
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice